Research ExplorerPublicationsImprovement of survival in sex cord stromal tumors - an obse...

Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up

Standard

Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up. / Hölscher, Gabriele; Anthuber, Christoph; Bastert, Gunther; Burges, Alexander; Mayr, Doris; Oberlechner, Ernst; Schubert-Fritschle, Gabriele; Sinz, Sonja; Sommer, Harald; Schmalfeldt, Barbara; Engel, Jutta; 'Malignant Ovarian Tumors' of the Munich Cancer Center (MCC).

In: ACTA OBSTET GYN SCAN, Vol. 88, No. 4, 2009, p. 440-8.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hölscher, G, Anthuber, C, Bastert, G, Burges, A, Mayr, D, Oberlechner, E, Schubert-Fritschle, G, Sinz, S, Sommer, H, Schmalfeldt, B, Engel, J & 'Malignant Ovarian Tumors' of the Munich Cancer Center (MCC) 2009, 'Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up', ACTA OBSTET GYN SCAN, vol. 88, no. 4, pp. 440-8. https://doi.org/10.1080/00016340902741208

APA

Hölscher, G., Anthuber, C., Bastert, G., Burges, A., Mayr, D., Oberlechner, E., Schubert-Fritschle, G., Sinz, S., Sommer, H., Schmalfeldt, B., Engel, J., & 'Malignant Ovarian Tumors' of the Munich Cancer Center (MCC) (2009). Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up. ACTA OBSTET GYN SCAN, 88(4), 440-8. https://doi.org/10.1080/00016340902741208

Vancouver

Hölscher G, Anthuber C, Bastert G, Burges A, Mayr D, Oberlechner E et al. Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up. ACTA OBSTET GYN SCAN. 2009;88(4):440-8. https://doi.org/10.1080/00016340902741208

Bibtex

@article{63866df9f9864d7e8b0c973c2d9c2728,
title = "Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up",
abstract = "OBJECTIVE: To highlight aspects of malignant ovarian sex cord stromal tumors, effects of treatment, and developments over the past 28 years.DESIGN: Population-based cohort study.SETTING: Gynecological departments within the catchment-area of the Munich Cancer Registry and associated with the project group 'Malignant Ovarian Tumors' of the Munich Cancer Center.SAMPLE: One hundred and forty-five women with an invasive single sex cord stromal tumor diagnosed between 1978 and 2005.METHODS: Overall survival was estimated with the Kaplan-Meier method, relative survival was computed by the ratio of observed to expected survival rate. The impact of age, International Federation of Gynecology and Obstetrics (FIGO)-stage, residual tumor, and chemotherapy was examined by multivariate analysis (Cox regression model).MAIN OUTCOME MEASURES: Overall and relative survival and multivariate adjusted overall survival.RESULTS: Survival data showed a five-/10-year overall survival of 55.8%/42.8% (relative survival 58.6%/49.2%) for women diagnosed before 1988 and 89.1%/78.3% (relative survival 92.7%/85.2%) for women diagnosed after 1988. After adjustment for age and FIGO-stage, the following hazard ratios and 95% confidence intervals (95% CI) for treatment methods resulted: 3.3 (95% CI 1.5-7.0) for women with compared to women without residual tumor and 2.2 (95% CI 1.2-4.2) for women with chemotherapy compared to women where no chemotherapy was given.CONCLUSIONS: Improvements in survival may be attributed to a stage-shift toward more favorable stages at diagnosis and to advances in treatment such as improved surgery without residual tumor. There is no evidence for any benefit of adjuvant chemotherapy. Surgery remains the cornerstone of treatment, yet the benefit of postoperative therapy is still under debate.",
keywords = "Age Factors, Antineoplastic Agents, Chemotherapy, Adjuvant, Cohort Studies, Combined Modality Therapy, Female, Follow-Up Studies, Germany, Humans, Kaplan-Meier Estimate, Middle Aged, Multivariate Analysis, Neoplasm Staging, Ovarian Neoplasms, Proportional Hazards Models, Registries, Risk Factors, Sex Cord-Gonadal Stromal Tumors, Survival Rate, Treatment Outcome",
author = "Gabriele H{\"o}lscher and Christoph Anthuber and Gunther Bastert and Alexander Burges and Doris Mayr and Ernst Oberlechner and Gabriele Schubert-Fritschle and Sonja Sinz and Harald Sommer and Barbara Schmalfeldt and Jutta Engel and {'Malignant Ovarian Tumors' of the Munich Cancer Center (MCC)}",
year = "2009",
doi = "10.1080/00016340902741208",
language = "English",
volume = "88",
pages = "440--8",
journal = "ACTA OBSTET GYN SCAN",
issn = "0001-6349",
publisher = "Wiley-Blackwell",
number = "4",

}

RIS

TY - JOUR

T1 - Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up

AU - Hölscher, Gabriele

AU - Anthuber, Christoph

AU - Bastert, Gunther

AU - Burges, Alexander

AU - Mayr, Doris

AU - Oberlechner, Ernst

AU - Schubert-Fritschle, Gabriele

AU - Sinz, Sonja

AU - Sommer, Harald

AU - Schmalfeldt, Barbara

AU - Engel, Jutta

AU - 'Malignant Ovarian Tumors' of the Munich Cancer Center (MCC)

PY - 2009

Y1 - 2009

N2 - OBJECTIVE: To highlight aspects of malignant ovarian sex cord stromal tumors, effects of treatment, and developments over the past 28 years.DESIGN: Population-based cohort study.SETTING: Gynecological departments within the catchment-area of the Munich Cancer Registry and associated with the project group 'Malignant Ovarian Tumors' of the Munich Cancer Center.SAMPLE: One hundred and forty-five women with an invasive single sex cord stromal tumor diagnosed between 1978 and 2005.METHODS: Overall survival was estimated with the Kaplan-Meier method, relative survival was computed by the ratio of observed to expected survival rate. The impact of age, International Federation of Gynecology and Obstetrics (FIGO)-stage, residual tumor, and chemotherapy was examined by multivariate analysis (Cox regression model).MAIN OUTCOME MEASURES: Overall and relative survival and multivariate adjusted overall survival.RESULTS: Survival data showed a five-/10-year overall survival of 55.8%/42.8% (relative survival 58.6%/49.2%) for women diagnosed before 1988 and 89.1%/78.3% (relative survival 92.7%/85.2%) for women diagnosed after 1988. After adjustment for age and FIGO-stage, the following hazard ratios and 95% confidence intervals (95% CI) for treatment methods resulted: 3.3 (95% CI 1.5-7.0) for women with compared to women without residual tumor and 2.2 (95% CI 1.2-4.2) for women with chemotherapy compared to women where no chemotherapy was given.CONCLUSIONS: Improvements in survival may be attributed to a stage-shift toward more favorable stages at diagnosis and to advances in treatment such as improved surgery without residual tumor. There is no evidence for any benefit of adjuvant chemotherapy. Surgery remains the cornerstone of treatment, yet the benefit of postoperative therapy is still under debate.

AB - OBJECTIVE: To highlight aspects of malignant ovarian sex cord stromal tumors, effects of treatment, and developments over the past 28 years.DESIGN: Population-based cohort study.SETTING: Gynecological departments within the catchment-area of the Munich Cancer Registry and associated with the project group 'Malignant Ovarian Tumors' of the Munich Cancer Center.SAMPLE: One hundred and forty-five women with an invasive single sex cord stromal tumor diagnosed between 1978 and 2005.METHODS: Overall survival was estimated with the Kaplan-Meier method, relative survival was computed by the ratio of observed to expected survival rate. The impact of age, International Federation of Gynecology and Obstetrics (FIGO)-stage, residual tumor, and chemotherapy was examined by multivariate analysis (Cox regression model).MAIN OUTCOME MEASURES: Overall and relative survival and multivariate adjusted overall survival.RESULTS: Survival data showed a five-/10-year overall survival of 55.8%/42.8% (relative survival 58.6%/49.2%) for women diagnosed before 1988 and 89.1%/78.3% (relative survival 92.7%/85.2%) for women diagnosed after 1988. After adjustment for age and FIGO-stage, the following hazard ratios and 95% confidence intervals (95% CI) for treatment methods resulted: 3.3 (95% CI 1.5-7.0) for women with compared to women without residual tumor and 2.2 (95% CI 1.2-4.2) for women with chemotherapy compared to women where no chemotherapy was given.CONCLUSIONS: Improvements in survival may be attributed to a stage-shift toward more favorable stages at diagnosis and to advances in treatment such as improved surgery without residual tumor. There is no evidence for any benefit of adjuvant chemotherapy. Surgery remains the cornerstone of treatment, yet the benefit of postoperative therapy is still under debate.

KW - Age Factors

KW - Antineoplastic Agents

KW - Chemotherapy, Adjuvant

KW - Cohort Studies

KW - Combined Modality Therapy

KW - Female

KW - Follow-Up Studies

KW - Germany

KW - Humans

KW - Kaplan-Meier Estimate

KW - Middle Aged

KW - Multivariate Analysis

KW - Neoplasm Staging

KW - Ovarian Neoplasms

KW - Proportional Hazards Models

KW - Registries

KW - Risk Factors

KW - Sex Cord-Gonadal Stromal Tumors

KW - Survival Rate

KW - Treatment Outcome

U2 - 10.1080/00016340902741208

DO - 10.1080/00016340902741208

M3 - SCORING: Journal article

C2 - 19191075

VL - 88

SP - 440

EP - 448

JO - ACTA OBSTET GYN SCAN

JF - ACTA OBSTET GYN SCAN

SN - 0001-6349

IS - 4

ER -